Trial Profile
Single Arm Clinical Study of Human Amniotic Epithelial Cells in Preventing Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Human amniotic epithelial cells-Shanghai-iCELL-Biotechnology (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms hAECs-GVHD
- 01 Jul 2020 Planned End Date changed from 1 Apr 2022 to 1 Jul 2022.
- 01 Jul 2020 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021.
- 01 Jul 2020 Status changed from not yet recruiting to recruiting.